Coagulopathy and platelet abnormalities in patients with inflammatory bowel disease
Authors:
Open Access
- 1 November 2025
- journal article
- review article
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 40 (6) , 866-875
Abstract
Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is associated with a hypercoagulable state that increases thromboembolic complication risk. The interaction between inflammation and coagulation increases risk by upregulating coagulation factors, downregulating natural anticoagulants, and impairing fibrinolysis. Patients with IBD exhibit elevated levels of prothrombotic markers, including thrombin-antithrombin complexes, von Willebrand factor, and tissue factor, reflecting persistent coagulation activation. Furthermore, platelet abnormalities, such as thrombocytosis, enhanced platelet reactivity, and increased platelet-leukocyte aggregates, contribute to the prothrombotic state. Impaired fibrinolysis, characterized by elevated plasminogen activator inhibitor-1 (PAI-1) and decreased urokinase plasminogen activator (uPA) levels, results in reduced clot degradation and prolonged thrombus stability. Endothelial dysfunction and immune-mediated disruptions in anticoagulant pathways also exacerbate coagulation abnormalities. The thromboembolic risk in patients with IBD is influenced by disease activity, hospitalization, immobility, and specific therapeutic agents. Certain treatments, such as JAK inhibitors, increase the risk, whereas anti-TNF agents may offer protective effects. Given the notable impact of coagulation and platelet dysfunction on IBD pathophysiology and patient outcomes, a comprehensive understanding of these abnormalities is essential to optimize clinical management and reduce critical thromboembolic complications.Keywords
This publication has 76 references indexed in Scilit:
- Shedding Light on Hemostasis in Patients With Inflammatory Bowel DiseasesClinical Gastroenterology and Hepatology, 2021
- Inflammatory Bowel Disease Therapy and Venous ThromboembolismCurrent Treatment Options in Gastroenterology, 2020
- Acute Venous Thromboembolism Risk Highest Within 60 Days After Discharge From the Hospital in Patients With Inflammatory Bowel DiseasesClinical Gastroenterology and Hepatology, 2020
- Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid ArthritisArthritis & Rheumatology, 2019
- Trimethylamine-N-Oxide, a Metabolite Associated with Atherosclerosis, Exhibits Complex Genetic and Dietary RegulationCell Metabolism, 2013
- Platelets at work in primary hemostasisBlood Reviews, 2011
- Thrombosis and inflammatory bowel disease: A call for improved awareness and preventionInflammatory Bowel Diseases, 2011
- Activated factor XI and tissue factor in inflammatory bowel diseaseInflammatory Bowel Diseases, 2010
- The Epidemiology of Venous Thromboembolism in the Community: Implications for Prevention and ManagementJournal of Thrombosis and Thrombolysis, 2006
- Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel diseaseDigestive Diseases and Sciences, 1995